Sagar Sandra, Raman Pratibha, Gheena S, Abilasha R, Krishnan Reshma Poothakulath, Selvaraj J
Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai 600077, India.
Bioinformation. 2022 Oct 31;18(10):884-887. doi: 10.6026/97320630018884. eCollection 2022.
Oral Squamous Cell Carcinoma comprises nearly 90% of all Oral cancers. Recent studies on Oral Squamous Cell Carcinoma are done with a focus on identification of factors that affect the outcome of treatment, one of which is vitamin D levels. The aim of this study was to evaluate vitamin D3 levels in patients with Oral Squamous Cell Carcinoma and Normal Population with saliva as a biomarker. The study sample comprised of 40 subjects, of whom 20 were patients diagnosed with OSCC and 20 healthy subjects. The salivary samples obtained were assessed using Vitamin D3 ELISA kit. The mean salivary Vitamin D3 levels were 39.09 ng/dl among OSCC patients and 44.49 ng/dl among healthy subjects. Salivary Vitamin D levels in OSCC patients were found to be significantly less compared to the healthy controls. More than 90% of cancers of the oral cavity are Oral Squamous Cell Carcinoma (OSCC). Recent studies are done with a focus on identification of factors affecting the treatment of cancer, one of which is vitamin D levels. The aim of the study was to evaluate salivary vitamin D3 levels in patients with Oral Squamous Cell Carcinoma and in Normal Population. 40 patients were selected for the study. Salivary samples collected were assessed using Vitamin D3 ELISA Kit-EDI Total 25-OH Vitamin D EIA Kit to detect the salivary vitamin D levels. Mean Salivary Vitamin D3 levels were found to be 39.09 ng/dl in OSCC patients and 44.49 ng/dl in healthy subjects. A salivary Vitamin D level in OSCC patients was found to be significantly less compared to the healthy controls. Decreased Vitamin D3 levels in patients with OSCC indicate that Vitamin D3 deficiency increases the rate of cell proliferation, invasion, angiogenesis & metastasis in patients with OSCC. Vitamin D level is likely to reduce the severity of the disease and hence Vitamin D supplementation for OSCC patients in the early stages of treatment and after treatment can be done to enhance the prognosis.
口腔鳞状细胞癌占所有口腔癌的近90%。最近关于口腔鳞状细胞癌的研究主要集中在确定影响治疗结果的因素,其中之一是维生素D水平。本研究的目的是以唾液作为生物标志物,评估口腔鳞状细胞癌患者和正常人群中的维生素D3水平。研究样本包括40名受试者,其中20名是被诊断为口腔鳞状细胞癌的患者,20名是健康受试者。使用维生素D3 ELISA试剂盒对采集的唾液样本进行评估。口腔鳞状细胞癌患者唾液中维生素D3的平均水平为39.09 ng/dl,健康受试者为44.49 ng/dl。与健康对照组相比,口腔鳞状细胞癌患者的唾液维生素D水平明显较低。超过90%的口腔癌是口腔鳞状细胞癌(OSCC)。最近的研究主要集中在确定影响癌症治疗的因素,其中之一是维生素D水平。该研究的目的是评估口腔鳞状细胞癌患者和正常人群中的唾液维生素D3水平。40名患者被选入该研究。使用维生素D3 ELISA试剂盒 - EDI总25 - OH维生素D EIA试剂盒对采集的唾液样本进行评估,以检测唾液维生素D水平。口腔鳞状细胞癌患者唾液维生素D3的平均水平为39.09 ng/dl,健康受试者为44.49 ng/dl。与健康对照组相比,口腔鳞状细胞癌患者的唾液维生素D水平明显较低。口腔鳞状细胞癌患者维生素D3水平降低表明,维生素D3缺乏会增加口腔鳞状细胞癌患者的细胞增殖、侵袭、血管生成和转移率。维生素D水平可能会降低疾病的严重程度,因此可以在治疗早期和治疗后对口腔鳞状细胞癌患者补充维生素D,以改善预后。